A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Jhaveri K, De Vita S, Crystal A, He W, Ji Y, Balbin A, Sheng Q, Kundamal N, Huober J, Takahashi S, Terret C, Duhoux F, Layman R, Cresta S, Yap Y, Juric D, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 2021
Aug 25, 2021
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Aug 25, 2021
Clin Cancer Res 2021
Jhaveri Komal, De Vita Serena, Crystal Adam, He Wei, Ji Yan, Balbin Alejandro, Sheng Qing, Kundamal Nicole, Huober Jens, Takahashi Shunji, Terret Catherine, Duhoux Francois P, Layman Rachel M, Cresta Sara, Yap Yoon-Sim, Juric Dejan, Curigliano Giuseppe
more
